Sanofi Has EU Insulin Aspart Biosimilar Approval
Firm Comments on Pricing And Launch Plans For Rival To NovoRapid
Sanofi has received formal approval from the European Commission for its insulin aspart biosimilar.
You may also be interested in...
Biocon and Viatris have landed their second biosimilar insulin approval in Europe, for a rival to Novo Nordisk’s NovoRapid (insulin aspart). Analyst reaction was lukewarm considering the “disappointing” launch of insulin glargine in Europe more than two years ago.
Viatris has received a positive opinion from the EMA’s CHMP recommending granting a pan-European marketing authorization for the firm’s insulin aspart biosimilar rival to NovoRapid.
While in possession of a token biosimilar portfolio and pipeline, Sanofi has made it clear that its R&D dollars are unlikely to be spent on biosimilars, six months after reshaping its pipeline by exiting diabetes and cardiovascular diseases research.